Page 8 - Rhythm Pharmaceuticals Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Profund Advisors LLC Sells 19,262 Shares of Rhythm Pharmaceuticals, Inc (NASDAQ:RYTM)

Profund Advisors LLC trimmed its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 40.9% in the 3rd quarter, Holdings Channel reports. The firm owned 27,818 shares of the company’s stock after selling 19,262 shares during the quarter. Profund Advisors LLC’s holdings in Rhythm Pharmaceuticals were worth $638,000 at the end of […]

Joseph shulmanHunterc smithRhythm pharmaceuticals profileDimensional fund advisorsHermes incRhythm pharmaceuticals stock performanceHoldings channelJpmorgan chase coRhythm pharmaceuticals incNeedham companyGoldman sachs groupSwiss national bankRhythm pharmaceuticalsMorgan stanleyNews ratings for rhythm pharmaceuticals dailyMetlife investment management

Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results, Hits Expectations

Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results, Hits Expectations
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Joseph shulmanHunterc smithJpmorgan chase coNews ratings for rhythm pharmaceuticals dailyRhythm pharmaceuticalsEarnings history for rhythm pharmaceuticalsSwiss national bankRhythm pharmaceuticals incMorgan stanleySecurities exchange commissionMetlife investment managementHermes incRhythm pharmaceuticals tradingInsider transactions at rhythm pharmaceuticalsGoldman sachs groupDimensional fund advisors

Rhythm Pharmaceuticals (NASDAQ:RYTM) Announces Earnings Results

Rhythm Pharmaceuticals (NASDAQ:RYTM) Announces Earnings Results
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesJoseph shulmanHunterc smithInstitutional trading of rhythm pharmaceuticalsAsset management americas incInsider activity at rhythm pharmaceuticalsEarnings history for rhythm pharmaceuticalsRhythm pharmaceuticalsRhythm pharmaceuticals price performanceNews ratings for rhythm pharmaceuticals dailyDeutsche bankMorgan stanleyRhythm pharmaceuticals incSecurities exchange commissionBoard of administration florida retirement systemWells fargo company

Rhythm Pharmaceuticals, Inc (NASDAQ:RYTM) Given Average Rating of Buy by Brokerages

Rhythm Pharmaceuticals, Inc (NASDAQ:RYTM) Given Average Rating of Buy by Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesHunterc smithJoseph shulmanRhythm pharmaceuticals company profileNeedham companyRhythm pharmaceuticalsLife insurance coAnalyst recommendations for rhythm pharmaceuticalsGoldman sachs groupRhythm pharmaceuticals stock performanceChina universal asset management coMorgan stanleyWells fargo companyNews ratings for rhythm pharmaceuticals dailyChicago partners investment groupInstitutional investors weigh in on rhythm pharmaceuticals

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 4 4%

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s share price was down 4.4% on Thursday . The stock traded as low as $43.43 and last traded at $46.68. Approximately 90,505 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 686,012 shares. The stock had previously closed at $48.81. […]

Joseph shulmanHunterc smithNeedham companyWells fargo companySilverarc capital managementSecurities exchange commissionVictory capital management incInstitutional investors weigh in on rhythm pharmaceuticalsNews ratings for rhythm pharmaceuticals dailyRhythm pharmaceuticals price performanceChina universal asset management coRhythm pharmaceuticalsBarclays plcMorgan stanleyRhythm pharmaceuticals incGoldman sachs group